Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy

…, PS Helliwell, A Latos-Bieleńska, SEV Phillips… - Nature …, 2008 - nature.com
Digital clubbing, recognized by Hippocrates in the fifth century BC, is the outward hallmark
of pulmonary hypertrophic osteoarthropathy, a clinical constellation that develops secondary …

Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis

…, DD Gladman, A Gottlieb, PS Helliwell… - Arthritis & …, 2016 - Wiley Online Library
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting …

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

LC Coates, J Fransen, PS Helliwell - Annals of the rheumatic diseases, 2010 - ard.bmj.com
Objective: To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With
recent therapeutic advances, this is now a goal for treatment and may represent a measure to …

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

…, DM Meads, P Emery, PG Conaghan, PS Helliwell - The Lancet, 2015 - thelancet.com
Background Early intervention and tight control of inflammation optimise outcomes in rheumatoid
arthritis but these approaches have not yet been studied in psoriatic arthritis. We aimed …

[HTML][HTML] Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

…, A Garg, DD Gladman, N Goel, PS Helliwell… - Nature Reviews …, 2022 - nature.com
Since the second version of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic …

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind …

A Deodhar, PS Helliwell, WH Boehncke, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…

Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis

PJ Healy, PS Helliwell - … Care & Research: Official Journal of …, 2008 - Wiley Online Library
Objective To assess currently available tools for measurement of enthesitis and to develop
a new instrument specifically for use in psoriatic arthritis (PsA). Methods Twenty‐eight …

Consensus on a core set of domains for psoriatic arthritis.

…, PJ Mease, V Strand, P Healy, PS Helliwell… - The Journal of …, 2007 - jrheum.org
A psoriatic arthritis (PsA) module was convened at OMERACT 8 in order to achieve
consensus on the core domains that should be included in randomized controlled trials and …

Comparison of disability and quality of life in rheumatoid and psoriatic arthritis.

KB Sokoll, PS Helliwell - The Journal of Rheumatology, 2001 - jrheum.org
OBJECTIVE: There is controversy about the severity of peripheral psoriatic arthritis (PsA)
compared to rheumatoid arthritis (RA). Early reports found PsA to be a milder disorder, …

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

PS Helliwell, O FitzGerald, J Fransen… - Annals of the …, 2013 - ard.bmj.com
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …